Released Nov 13, 2023, after the close
10-Q filed Nov 13, 2023, 44 days after period end · 0000950170-23-062897
Q3 2023 · 10-Q
Revenue$218.00K$218.00K −79.9% vs Q3 2022−19.0% vs Q2 2023
Net Income-$3.20M-$3.20M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.06-$0.06 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$1,934,000N/M
Operating Cash Flowderived$15,915,000N/M
Margins · derived
Operating margin-887.2%+206.6 pt vs Q3 2022
Net margin-1467.9%−386.6 pt vs Q3 2022
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $218.00K | $1.08M | $708.00K | $38.00K |
| Net Income | -$3.20M | -$11.70M | -$22.50M | -$18.90M |
| EPS Diluted | -$0.06 | -$0.33 | -$0.70 | -$0.86 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR